Purpose: To determine the potential suitability of the 25-item National Eye Institute Visual Function Questionnaire (NEI VFQ-25) for measuring health-related quality of life (HRQL) in patients with Graves' ophthalmopathy.

Design: Cross-sectional study.

Participants: Thirty adult patients with mild to severe Graves' ophthalmopathy.

Methods: Participants self-administered the NEI VFQ-25 and completed a semistructured interview to provide feedback about the questionnaire. The percentage of responses at the maximum and minimum value was calculated to assess ceiling and floor effects, respectively, for the 12 subscales of the NEI VFQ-25. The NEI VFQ-25 scores were compared for Graves' ophthalmopathy patients who reported symptomatic diplopia and those who did not report diplopia using univariate and multivariate linear regression models.

Main Outcome Measures: The NEI VFQ-25 subscale and composite scores.

Results: Health-related quality of life in those with Graves' ophthalmopathy was moderately impaired, with median composite score of 69. The greatest impairment was measured in the Mental Health (median, 50) and the Role Difficulties (median, 50) subscales. Significant ceiling effects were seen in 7 of the 12 subscales. More than two thirds of Graves' ophthalmopathy patients perceived that the NEI VFQ-25 lacked items relevant to their disease. The NEI VFQ-25 scores were lower for those with diplopia symptoms (composite score, 61) compared with those without diplopia (composite score, 90). Comparing these 2 groups, the largest differences were measured in the Driving and Peripheral Vision subscales.

Conclusions: The NEI VFQ-25 includes many items that are applicable to Graves' ophthalmopathy patients. However, it shows significant ceiling effects in more than half of the subscales and it lacks items on issues that are important to Graves' ophthalmopathy patients, such as altered appearance and ocular discomfort. Efforts to develop an HRQL instrument that adds Graves' ophthalmopathy-specific items to relevant aspects of the NEI VFQ-25 are warranted.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ophtha.2006.02.060DOI Listing

Publication Analysis

Top Keywords

nei vfq-25
36
graves' ophthalmopathy
24
ophthalmopathy patients
16
composite score
12
graves'
9
nei
9
vfq-25
9
national eye
8
eye institute
8
institute visual
8

Similar Publications

Chronic ocular pain impacts quality of life and is often linked to ocular surgery. We assessed the prevalence of chronic postoperative pain (CPOP) after cataract surgery and associated risk factors using a secondary cohort post-hoc analysis of data from the Age-Related Eye Disease Study (AREDS), a multicenter, controlled, randomized clinical trial of antioxidant vitamins and minerals. Ocular pain was determined from item 4 of the National Eye Institute Visual Function Questionnaire (NEI-VFQ-25), administered between 1997 and 2005.

View Article and Find Full Text PDF
Article Synopsis
  • The study investigates the long-term safety and efficacy of lenadogene nolparvovec, a gene therapy for Leber hereditary optic neuropathy (LHON) caused by the MT-ND4 gene variant, enrolling patients for up to 5 years after treatment.
  • Conducted between 2018 and 2022, the RESTORE trial followed patients who previously participated in two phase 3 studies, RESCUE and REVERSE, focusing on vision loss treatment; most participants were male with an average age of 35.9 years.
  • Results indicated that 94.7% of participants completed the initial studies, and 72.4% completed the 5-year follow-up, with key outcomes
View Article and Find Full Text PDF

Purpose: To derive estimates of clinically meaningful change (improvement) on the 25-item National Eye Institute Visual Function Questionnaire (NEI VFQ-25) in patients with diabetic macular edema (DME) using anchor- and distribution-based methods.

Methods: In this exploratory post hoc analysis of data from the RIDE/RISE (NCT00473382/NCT00473330) clinical trials of ranibizumab for DME, the NEI VFQ-25 was completed at baseline and six, 12, 18, and 24 months. Anchor-based (≥5-, ≥10-, and ≥15-letter gain in best-corrected visual acuity [BCVA]) and distribution-based estimates were calculated.

View Article and Find Full Text PDF
Article Synopsis
  • Subjective visual impairment (VI) is linked to cognitive performance in both cognitively unimpaired (CU) older adults and patients with mild cognitive impairment (MCI) or Alzheimer's disease (AD).
  • The study used the NEI-VFQ-25 and a neuropsychological test to explore this relationship, finding that CU adults had a positive link between subjective VI and visuospatial abilities.
  • Results suggest that subjective VI complaints could serve as indicators for specific cognitive decline areas like attention, processing speed, and executive function in older individuals.
View Article and Find Full Text PDF

Quality of Life Survey Using NEI VFQ-25 in Japanese Patients With Fuchs Endothelial Corneal Dystrophy.

Eye Contact Lens

December 2024

Department of Ophthalmology (K.Y., Y.O., N.N., S.M., C.K., M.K., Reiko Kobayashi, T.S., S.K., K.N.), Osaka University Graduate School of Medicine, Suita, Osaka, Japan; and Division of Public Health (Ryo Kawasaki), Department of Social Medicine, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.

Objectives: To assess the quality of life in Japanese patients with Fuchs endothelial corneal dystrophy (FECD) using The National Eye Institute Visual Function Questionnaire.

Methods: Here, 34 patients with FECD (FECD group) and 13 healthy individuals (control group) completed the National Eye Institute Visual Function Questionnaire Japanese version by interview format. The association between dominant eye corrected distance visual acuity and composite score (component 11) or subscales in the FECD group was evaluated using Spearman rank correlation coefficient.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!